BPMC (Blueprint Medicines) Earnings growth in current year

Official company branding of Blueprint Medicines Corporation (BPMC)

Promotion costs for Ayvakit and R&D investments are slowing Blueprint Medicines (BPMC) from achieving net profit. Meanwhile, robotic target screening is optimizing headcount through automation. The annual EPS change scale visualizes the dynamics of this process, where 25.30 serves as the current metric marker. An environmental approach and green chemistry principles complete the company's sustainable development strategy.

BPMC (Blueprint Medicines Corp.) Earnings growth in current year history from 07/04/2022 to 08/02/2025

Comprehensive metric breakdowns and analytics for blueprintmedicines.com (BPMC)

Fundamental valuation:BPMC Blueprint Medicines
Signature product of Blueprint Medicines

This indicator measures the annual growth of earnings per share, capturing the rate of change in net yield relative to the same period last year. Investors should interpret the percentage deviation of EPS from the previous year as a marker of operational resilience and the issuer's ability to generate free cash flow. For Blueprint Medicines (BPMC), this metric reflects the efficiency of commercializing targeted therapies within the rare oncological mutation segment.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Inc.) - Earnings growth in current year|Earnings growth in current year nuvalent.com|Earnings per share growth in current year Kymera (KYMR)|IDYA (IDEAYA Biosciences, Inc.) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics Inc)|Net earnings per share change in current year ORIC Pharma|Relay Therapeutics Inc - Earnings growth in current year|Earnings per share growth rate in current year Nurix Therapeutics, Inc.|TYRA (Tyra Biosciences, Inc.) - Net earnings per share growth this year|VSTM: Net earnings per one share growth for the current year|GLUE (monterosatx.com) - Earnings growth in current year|Earnings per share growth rate in current year Cullinan Therapeutics Inc CGEM|Earnings growth in current year IMRX|C4 Therapeutics - Earnings per share growth this year|Black Diamond Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year RPTX|PMVP: Net earnings per share growth this year|karyopharm.com - Net earnings per one share growth for the current year|PPCB: Earnings growth in current year|Bio Green Med Solution Inc - Earnings per share increase in current year|AADI (Aadi Bioscience Inc) - Earnings growth in current year|Earnings per share growth rate in current year aileronrx.com ALRN|Earnings per share growth in current year GlycoMimetics Inc. (GLYC)|SWTX (SpringWorks) - Earnings per share increase in current year